Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
New research suggests that ketamine can aid in reorganizing alcohol-related memories.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Placebo-Controlled Study Finds Psilocybin Formulation is Safe and Well-Tolerated in Healthy Volunteers
The study used an investigational psilocybin formulation called COMP360 developed and produced by COMPASS Pathways.
These bluing compounds can exist as dimeric, trimeric, and tetrameric forms of psilocin and/or its structural analogs.
A recent Nature paper provides novel insights into the neural correlates of the Breakthrough Experience associated with DMT.
Identifying and understanding prodrugs is an essential component of psychedelic drug research.
The study will examine the effects of microdosing LSD on the everyday lives of the participants.
This new crystal form presents new options for developing psychedelics into therapeutic drug formulations.